October 24, 2024, Shenzhen — SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (hereinafter referred to as "IONOVA") today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has cleared the investigational new drug (IND) application for INV-9956.
INV-9956, a potent, selective, and orally bioavailable CYP11A1 inhibitor, is an investigational candidate for the treatment of castration-resistant prostate cancer (CRPC). The investigational candidate has exhibited a superior overall profile in preclinical studies. IONOVA previously announced that the U.S. Food and Drug Administration (FDA) cleared IND application for INV-9956 in July.
About IONOVA
IONOVA is a clinical-stage biotech company dedicated to developing next-generation cancer therapeutics that offer distinct clinical benefits and global competitiveness.
